Drug combination assays using Caenorhabditis elegans as a model system

被引:2
|
作者
Hernando, Guillermina [1 ]
Bouzat, Cecilia [1 ]
机构
[1] Univ Nacl Sur UNS, Dept Biol Bioquim & Farm, Inst Invest Bioquim Bahia Blanca, CONICET, RA-8000 Bahia Blanca, Argentina
关键词
Drug combination; Synergistic effect; Nematode; Anthelmintic drug; Drug resistance; Locomotion assays; Pharmacological treatments; Thymol; Levamisole; DISCOVERY;
D O I
10.1016/j.vascn.2025.107583
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The C. elegans drug combination assay evaluates the effects of drug combinations in the nematode Caenorhabditis elegans, serving as a valuable tool to assess the efficacy of pharmaceutical agents and natural compounds. Using C. elegans as a model organism, this method allows for the efficient screening of the combined effects of different drugs and evaluation of synergistic effects in drug combinations, which reduces the risk of developing drug resistance. Combination therapy, involving commercial drugs, new agents, or natural products, broadens treatment effectiveness by targeting multiple pathways, effectively managing complex diseases with minimized side effects. The method focuses on discovering effective drug combinations, such as anthelmintic drugs, streamlining earlystage drug discovery to save time and resources. Additionally, its versatility allows for application across most areas of pharmacology and toxicology, extending its usefulness beyond anthelmintic treatments. In the experiments, synchronized worms are exposed to different drug concentrations to evaluate behavioral changes, mostly alterations in worm locomotion. Concentration-response curves for changes in behavior are generated and EC50 or IC50 values determined for the individual drugs. To determine whether the effects of a drug combination are synergistic, additive, or antagonistic, at least three different concentration ratios must be tested. These combinations are then analyzed using specialized drug combination analysis software. This methodology ensures consistent and precise outcomes and evaluates drug impacts on worm behavior parameters crucial for effective pharmacological activity. In conclusion, the C. elegans drug combination assay provides critical insights for developing successful market formulations applicable across a wide range of pharmacological treatments. Its ability to efficiently screen for synergistic, additive, or antagonistic effects makes it a valuable tool for identifying effective therapeutic strategies, potentially reducing drug resistance and improving treatment outcomes in various medical and toxicological fields.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Caenorhabditis elegans as a Model System for Duchenne Muscular Dystrophy
    Ellwood, Rebecca A.
    Piasecki, Mathew
    Szewczyk, Nathaniel J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [22] Antioxidant capacity of sesamol in Caenorhabditis elegans model system
    Jinian Huang
    Shuning Qi
    Qiang Sun
    Guohui Song
    Jixing Tang
    Yuquan Duan
    Food Production, Processing and Nutrition, 6
  • [23] Genetic kidney diseases: Caenorhabditis elegans as model system
    Ganner, Athina
    Neumann-Haefelin, Elke
    CELL AND TISSUE RESEARCH, 2017, 369 (01) : 105 - 118
  • [24] Caenorhabditis elegans as an emerging model system in environmental epigenetics
    Weinhouse, Caren
    Truong, Lisa
    Meyer, Joel N.
    Allard, Patrick
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2018, 59 (07) : 560 - 575
  • [25] Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification
    Kobetl, Robert A.
    Pan, Xiaoping
    Zhang, Baohong
    Pak, Stephen C.
    Asch, Adam S.
    Lee, Myon-Hee
    BIOMOLECULES & THERAPEUTICS, 2014, 22 (05) : 371 - 383
  • [26] Antioxidant capacity of sesamol in Caenorhabditis elegans model system
    Huang, Jinian
    Qi, Shuning
    Sun, Qiang
    Song, Guohui
    Tang, Jixing
    Duan, Yuquan
    FOOD PRODUCTION PROCESSING AND NUTRITION, 2024, 6 (01)
  • [27] Genetic kidney diseases: Caenorhabditis elegans as model system
    Athina Ganner
    Elke Neumann-Haefelin
    Cell and Tissue Research, 2017, 369 : 105 - 118
  • [28] Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique
    Ding, Xianting
    Njus, Zach
    Kong, Taejoon
    Su, Wenqiong
    Ho, Chih-Ming
    Pandey, Santosh
    SCIENCE ADVANCES, 2017, 3 (10):
  • [29] Stenotrophomonas maltophilia: pathogenesis model using Caenorhabditis elegans
    Thomas, Renjan
    Hamat, Rukman Awang
    Neela, Vasanthakumari
    JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 62 : 1777 - 1779
  • [30] Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development
    Zheng, Jolene
    Vasselli, Joseph R.
    King, Jason F.
    King, Michael L.
    We, Wenqian
    Fitzpatrick, Zachary
    Johnson, William D.
    Finley, John W.
    Martin, Roy J.
    Keenan, Michael J.
    Enright, Frederic M.
    Greenway, Frank L.
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (06) : E1363 - E1370